Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.

about

Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them?

P2860

Q47226752-D90E9C8D-74C2-4C96-91A7-0BACEDE50114

P2860

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.

Item

http://www.wikidata.org/entity/Q50054965

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Investigation of Pump Compatib ...... Subjects With Type 1 Diabetes.

@en

Investigation of Pump Compatib ...... Subjects With Type 1 Diabetes.

@nl

type

Item

label

Investigation of Pump Compatib ...... Subjects With Type 1 Diabetes.

@en

Investigation of Pump Compatib ...... Subjects With Type 1 Diabetes.

@nl

prefLabel

Investigation of Pump Compatib ...... Subjects With Type 1 Diabetes.

@en

Investigation of Pump Compatib ...... Subjects With Type 1 Diabetes.

@nl

P1476

Investigation of Pump Compatib ...... Subjects With Type 1 Diabetes.

@en

P2093

Bruce Bode

http://www.w3.org/2001/XMLSchema#string

Eric Zijlstra

http://www.w3.org/2001/XMLSchema#string

Leszek Nosek

http://www.w3.org/2001/XMLSchema#string

Marek Demissie

http://www.w3.org/2001/XMLSchema#string

Tim Heise

http://www.w3.org/2001/XMLSchema#string

Tina Graungaard

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus

Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.

Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.

Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.

Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.

Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.

Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review.

Moving toward the ideal insulin for insulin pumps.

P304

145-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1932296817730375

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28918652

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

5761985

http://www.w3.org/2001/XMLSchema#string

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.

about

P2860

P2860

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932